Diagnostic sensitivity of imaging modalities for hepatocellular carcinoma smaller than 2 cm

Keiji Mita, Soo Ryang Kim, Masatoshi Kudo, Susumu Imoto, Taisuke Nakajima, Kenji Ando, Katsumi Fukuda, Toshiyuki Matsuoka, Yoko Maekawa, Yoshitake Hayashi

AIM: To compare the imaging results with histology and to evaluate the diagnostic sensitivity of imaging modalities for hepatocellular carcinoma (HCC) smaller than 2 cm.

METHODS: Nodules smaller than 2 cm (n = 34) revealed by ultrasonography (US) in 29 patients with liver cirrhosis were analyzed. Histological diagnosis of HCC was performed by ultrasonographic guidance: moderately-differentiated HCC (n = 24); well-differentiated HCC (n = 10). The patterns disclosed by the four imaging modalities defined the conclusive diagnosis of HCC: (1) contrast-enhanced computed tomography (CECT), hypervascularity in the arterial phase and washout in the equilibrium phase; (2) Sonazoid contrast-enhanced US (CEUS), hypervascularity in the early vascular phase and defect in the Kupffer phase; (3) gadolinium-ethoxybenzyl-diethylenetriamine pentaacetic acid (Gd-EOB-DTPA)-enhanced magnetic resonance imaging (MRI), hypervascularity in the arterial phase and/or defect in the hepatobiliary phase; and (4) CT arterioportal angiography: hypervascularity by CT during arteriography and/or perfusion defect by CT during arterial portography.

RESULTS: Overall, the sensitivity of diagnosing HCC smaller than 2 cm was 52.9% (18/34) (95% CI: 35.1-70.2) by CECT; 67.6% (23/34) (95% CI: 49.5-82.6) by Sonazoid CEUS; 76.5% (26/34) (95% CI: 58.8-89.3) by Gd-EOB-DTPA MRI; and 88.2% (30/34) (95% CI: 72.5-96.7) by CT arterioportal angiography. The diagnostic sensitivity of detecting moderately-differentiated HCC by CECT, Sonazoid CEUS, Gd-EOB-DTPA MRI and CT arterioportal angiography was 62.5% (15/24) (95% CI: 40.6-81.2), 79.2% (19/24) (95% CI: 57.8-92.9), 75.0% (18/24) (95% CI: 53.3-90.2) and 95.8% (23/24) (95% CI: 78.9-99.9), respectively. A significant difference (P < 0.05) was observed between CECT and CT arterioportal angiography in all nodules. There was no difference between Sonazoid CEUS, Gd-EOB-DTPA MRI, and CT arterioportal angiography. The combined sensitivity of Sonazoid CEUS and Gd-EOB-DTPA MRI was 94.1% (32/34).

CONCLUSION: Changing the main diagnostic modality for HCC smaller than 2 cm from CT arterioportal angiography to Sonazoid CEUS and Gd-EOB-DTPA MRI is recommended.

© 2010 Baishideng. All rights reserved.

Key words: Computed tomography arterioporal angiography; Contrast-enhanced computed tomography; Diagnostic sensitivity; Gd-EOB-DTPA-enhanced magnetic resonance imaging.
resonance imaging; Hepatocellular carcinoma smaller than 2 cm: Sonazoid contrast-enhanced ultrasonography

Peer reviewers: Søren Rafaelsen, MD, Consultant Radiologist, Associate Professor, Department of Radiology, Vejle Hospital, Vejle, 7100, Denmark; Bernardo Frider, MD, Professor, Department of Hepatology, Hospital General de Agudos Cosme Argerich, Alte Brown 240, Buenos Aires 1155, Argentina

Mita K, Kim SR, Kudo M, Imoto S, Nakajima T, Ando K, Fukuda K, Matsuoka T, Maekawa Y, Hayashi Y. Diagnostic sensitivity of imaging modalities for hepatocellular carcinoma smaller than 2 cm. World J Gastroenterol 2010; 16(33): 4187-4192. Available from: URL: http://www.wjgnet.com/1007-9327/full/v16/i33/4187.htm DOI: http://dx.doi.org/10.3748/wjg.v16.i33.4187

INTRODUCTION
The definitive diagnosis of nodular lesions, detected by imaging techniques in the liver with cirrhosis, remains a critical challenge for clinicians. The issue is particularly complicated for small (1-2 cm) nodules, many of which may be preneoplastic with uncertain malignant potential[2-4], such as macrorregenerative nodules, low-grade dysplastic nodules (LGDN) or high-grade dysplastic nodules (HGDN), or more rarely, hemangiomas that are found in up to 42% of explanted livers[5-7].

Recently, clinicians have been able to conduct computed tomography (CT) scanning during angiography, thereby acquiring data on lesions and intranodular blood flow simultaneously[8,9]. To resolve the areas of uncertainty, we have previously reported on the superiority of CT arteriopetal angiography [including CT during arteriography (CTA) and CT during arterioportal portography (CTAP)], concluding that it is superior to contrast-enhanced CT (CECT) and magnetic resonance imaging (MRI) in the diagnosis of hepatocellular carcinoma (HCC) nodules smaller than 2 cm[2].

Moreover, development of the newly introduced diagnostic imaging techniques, Sonazoid contrast-enhanced ultrasonography (CEUS) and gadolinium-ethoxybenzyl-diethylenetriamine pentaacetic acid (Gd-EOB-DTPA)-enhanced MRI have provided higher degrees of detectability for small HCC. In this study, we compared the diagnostic sensitivity of CECT, Sonazoid CEUS, Gd-EOB-DTPA MRI, and CT arteriopetal angiography in diagnosing HCC in nodules smaller than 2 cm.

MATERIALS AND METHODS

Patients
From April 2008 to December 2009, we analyzed 34 nodules smaller than 2 cm [8-20 mm; mean ± SD 12.7 ± 3.71 mm; the interquartile range (IQR) 10-15 mm] detected by US in 29 patients (13 men and 16 women; aged 55-84 years; mean ± SD 70.5 ± 7.96 years; IQR 67-76 years) with liver cirrhosis related to hepatitis B virus in 1, hepatitis C virus (HCV) in 24, and alcohol in 4. α-fetoprotein (AFP) measured less than 20 ng/mL in 21 patients and was above 21 ng/mL in 8 (Table 1). In this study, one nodule that was not histologically diagnosed as HCC irrespective of compatibility by imaging studies was excluded, and two nodules were excluded because of inconsistency between readers in the imaging results. The study was approved by the Ethics Committee in Kobe Asahi Hospital.

CECT
CECT was conducted with the use of helical CT (Siemens, Germany) with precontrast and postcontrast triple-phase (arterial, portal, venous, and equilibrium phases) scans, after the injection of 120 mL of nonionic contrast medium at 3 mL/s; the scans were carried out in a craniocaudal direction with a 5 mm collimation in the other phases. Acquisition of the arterial and equilibrium phases was automatically started at 30 and 180 s, respectively, after the intravenous injection.

CEUS
Ultrasonography was performed using a SSA-660A (Toshiba Medical Systems, Tochigi, Japan). The vascular findings on phase-inversion harmonic US were shown as tumor vessel flow in the early vascular phase about 15-40 s after injection of Sonazoid (GE HealthCare, Piscataway, NJ, USA). The real-time replenishing images were obtained during the vascular phase (< 2 min after the injection) by release burst imaging. Images of the liver parenchyma were obtained in the postvascular Kupffer phase, at least 10 min after the intravenous injection of Sonazoid. Hepatic malignancies were visualized as defects in the postvascular phase. An additional contrast agent was injected to confirm tumor vessel flow in the defect, a technique known as defect reperfusion imaging[10].

Gd-EOB-DTPA MRI
Images by MRI scans (Phillips, Netherlands) were obtained by the 1.0-T superconducting system (Gyrosan 10T-NT, Phillips, Netherlands). Enhanced MRI was used to obtain
Hypervascularity in the arterial phase and washout in the equilibrium phase

September 7, 2010

Hypervascularity in the arterial phase and/or defect in the hepatobiliary phase

Hypervascularity in the early vascular phase and defect in the Kupffer phase

Imaging pattern

Table 2 Imaging patterns for the conclusive diagnosis of hepatocellular carcinoma by the four modalities

| Modality                                      | Imaging pattern                                      |
|----------------------------------------------|------------------------------------------------------|
| Contrast-enhanced CT                         | Hypervascularity in the arterial phase and washout in the equilibrium phase |
| Sonazoid contrast-enhanced ultrasonography   | Hypervascularity in the early vascular phase and defect in the Kupffer phase |
| Gd-EOB-DTPA magnetic resonance imaging       | Hypervascularity in the arterial phase and/or defect in the hepatobiliary phase |
| CT arteriportal angiography                  | Hypervascularity by CT A and/or perfusion defect by CTAP |

CT: Computed tomography; CTA: CT during arteriography; CTAP: CT during arterial portography; Gd-EOB-DTPA: Gadolinium-ethoxybenzyldiethylenetriamine pentaacetic acid.

coronal images by the gradient-echo technique (FFG) at 150/3.5 ms TR/TE, 80° flip angle, and 168 × 256 matrix. In each sequence, the respiration suspension time was 20−30 s. Gd-EOB-DTPA (Primovist; Bayer HealthCare, Osaka, Japan) at a dose of 0.025 mmol/kg body weight was injected intravenously as a rapid bolus at 2 mL/s. Dynamic contrast-enhanced MRI was initiated at 30 s, 70 s, 2−3 min and 20 min after the start of the bolus injection to obtain multiphasic (arterial, portal, late, and hepatobiliary) images.

CT arteriportal angiography (CTA and CTAP)

CTA: At angiography, 45 mL of diluted contrast medium was injected through a catheter at 2 mL/s into the common hepatic artery. The whole liver was then scanned at intervals of 5 to 10 mm.

CTAP: At angiography, 115 mL of diluted contrast medium was injected through a catheter at 2 mL/s into the superior mesenteric artery, according to the scanning time of the entire liver using a power injector during sequential scanning of the liver with incremental changes in the position of the table. Infusion of contrast material was initiated 20 s before CTAP. The whole liver was then scanned at intervals of 5 to 10 mm.

US-guided biopsy

US-guided biopsy was carried out with the use of a 21 gauge Majima needle (Top, Japan). The diagnosis of HCC was made by two operators [a physician (K.S.) and a pathologist (Y.H.)] using the same specimen.

Histological diagnosis

Specimens were routinely processed and stained with hematoxylin and eosin and by the Masson trichromatic method. The diagnosis of HCC was made according to the criteria of the International Working Party[6].

Imaging patterns for the conclusive diagnosis of HCC by the four modalities

The following patterns disclosed by the four imaging modalities were defined as the conclusive diagnosis of HCC. (1) CECT: hypervascularity in the arterial phase and washout in the equilibrium phase; (2) Sonazoid CEUS: hypervascularity in the early vascular phase and defect in the Kupffer phase; (3) Gd-EOB-DTPA MRI: hypervascularity in the arterial phase and/or defect in the hepatobiliary phase; and (4) CT arteriportal angiography: hypervascularity by CT A and/or perfusion defect by CTAP (Table 2).

Imaging studies

To minimize differences in the results between the operators, imaging studies were carried out and reviewed by two operators [a physician (M.K.) and a radiologist (T.M.)] using the same examination protocol.

Statistical analysis

The sensitivity for detecting tumors was indicated by the 95% CI. The 95% CI was estimated by F distribution. The level of significance was set at \( P < 0.05 \).

RESULTS

The 34 nodules were histologically diagnosed as moderately-differentiated (24 nodules) and well-differentiated (10 nodules) HCC (Table 1). For HCC smaller than 2 cm, the overall diagnostic sensitivity was 52.9% (18/34) (95% CI: 35.1-70.2) by CECT; 67.6% (23/34) (95% CI: 49.5-82.6) by Sonazoid CEUS; 76.5% (26/34) (95% CI: 58.8-89.3) by Gd-EOB-DTPA MRI; and 88.2% (30/34) (95% CI: 72.5-96.7) by CT arteriportal angiography, with a significant difference (\( P < 0.05 \)) between CECT and CT arteriportal angiography. The combined sensitivity of Sonazoid CEUS and Gd-EOB-DTPA MRI was 94.1% (32/34). In diagnosing moderately-differentiated HCC, the diagnostic sensitivity of CECT, Sonazoid CEUS, Gd-EOB-DTPA MRI and CT arteriportal angiography was 62.5% (15/24) (95% CI: 40.6-81.2), 79.2% (19/24) (95% CI: 57.8-92.9), 75.0% (18/24) (95% CI: 53.3-90.2) and 95.8% (23/24) (95% CI: 78.9-99.9), respectively. There was no difference between CECT, Sonazoid CEUS, Gd-EOB-DTPA MRI, and CT arteriportal angiography in moderately differentiated HCC. The sensitivity of well-differentiated HCC was not analyzed because of the paucity of cases (Table 3).

Representative cases

Case No. 1: Detection by Gd-EOB-DTPA MRI and arteriportal angiography: In a 67-year-old woman with HCV-related liver cirrhosis (AFP 9.0 ng/mL; PIVKA II 21 mAU/mL), US revealed a 12 mm hyperechoic nodule in segment eight (Figure 1A). Sonazoid CEUS revealed no hypervascularity in the early vascular phase and no defect in the Kupffer phase. CECT revealed no hypervascularity in the arterial phase and washout in the equilibrium phase.
Gd-EOB-DTPA MRI revealed no hypervascularity in the arterial phase, but a defect in the hepatobiliary phase (Figure 1B). CTA revealed isodensity (Figure 1C), and CTAP a perfusion defect (Figure 1D). US-guided biopsy revealed moderately-differentiated HCC (Figure 1E).

Case No. 2: Detection by Gd-EOB-DTPA MRI: In a 74-year-old woman with HCV-related liver cirrhosis (AFP 7.1 ng/mL, PIVKA II 42 mAU/mL), US revealed an 8 mm hyperechoic nodule in segment six (Figure 2A). Sonazoid contrast-enhanced ultrasonography revealed no hypervascularity in the early vascular phase and no defect in the Kupffer phase. CECT revealed isodensity in both the arterial phase and the equilibrium phase. MRI revealed isointensity. Gd-EOB-DTPA MRI revealed no hypervascularity in the early phase, but disclosed a defect in the hepatobiliary phase (Figure 2B). CTA revealed no hypervascularity and CTAP no perfusion defect. US-guided biopsy revealed well-differentiated HCC (Figure 2C).

DISCUSSION

Confirmation of arterial hypervascularity by three imaging modalities (triphasic CT, triphasic MRI, and CEUS), even in the absence of a significant (> 400 ng/mL) rise in AFP, is recommended by the European Association for the Study of the Liver (EASL) as diagnostic criteria for HCC nodules larger than 2 cm in patients with cirrhosis. These recommendations for the management of HCC provide a rational approach to the problem but leave some areas of uncertainty, particularly those regarding the interpretation of discordant vascularity, the use of imag-

### Table 3  Diagnostic sensitivity of hepatocellular carcinoma by the four modalities

| Modality                                           | All nodules (n = 34) |         |         | Moderately-differentiated HCC (n = 24) |         |
|----------------------------------------------------|----------------------|---------|---------|---------------------------------------|---------|
|                                                    | n (%)                | 95% CI  | n (%)   | 95% CI                                |         |
| Contrast-enhanced computed tomography              | 18 (52.9)            | 35.1-70.2| 15 (62.5)| 40.6-81.2                             |         |
| Sonazoid contrast-enhanced ultrasonography         | 23 (67.6)            | 49.5-82.6| 19 (79.2)| 57.8-92.9                             |         |
| Gd-EOB-DTPA magnetic resonance imaging            | 26 (76.5)            | 58.8-89.3| 18 (75.0)| 53.3-90.2                             |         |
| Computed tomography arteriportal angiography       | 30 (88.2)            | 72.5-96.7| 23 (95.8)| 78.9-99.9                             |         |

Gd-EOB-DTPA: Gadolinium-ethoxybenzyl-diethylenetriamine pentaacetic acid; HCC: Hepatocellular carcinoma.

Figure 1  Case No. 1: detection by gadolinium-ethoxybenzyl-diethylenetriamine pentaacetic acid magnetic resonance imaging and computed tomography arteriportal angiography. Imaging and histological findings of the nodule in segment eight. A: Ultrasonography (US) reveals a 12 mm hyperechoic nodule (arrow); B: Gadolinium-ethoxybenzyl-diethylenetriamine pentaacetic acid magnetic resonance imaging reveals a defect (arrow) in the hepatobiliary phase; C, D: Computed tomography during arteriography reveals isodensity (C) and computed tomography during arterial portography (D) reveals a perfusion defect (arrow); E: The nodule is diagnosed as moderately-differentiated hepatocellular carcinoma by US-guided biopsy.
ing techniques in nodules smaller than 2 cm, the meaning of truly hypovascular nodules, and the management of those diagnosed with LGDN or HGDN at guided biopsy.

The American Association for the Study of Liver Diseases\cite{11} recommends that the diagnosis of HCC should be made without biopsy when characteristic arterial vascularization and venous washout are observed on three imaging modalities: triphasic CT scan, triphasic MRI and contrast-enhanced harmonic US.

Nevertheless, these recommendations have not been tested and validated except by Bolondi \textit{et al}\cite{10} and Forner \textit{et al}\cite{13,14}. According to Bolondi \textit{et al}\cite{10}, the noninvasive EASL criteria with CEUS and CECT for the diagnosis of HCC are satisfied in only 44% of nodules smaller than 2 cm in cirrhosis. Forner \textit{et al}\cite{13} reported that the diagnostic sensitivity of MRI and CEUS in the diagnosis of HCC (smaller than 2 cm) is 67%.

The main characteristics of Sonazoid, a newly introduced second-generation US contrast agent exclusively approved in Japan in 2007, are that it facilitates real-time blood flow images at low acoustic power and stable Kupffer phase imaging from 10 to 120 min after its injection. In vascular imaging, Sonazoid is considered more effective than Levovist and easy to use; it allows visualization, even with the use of non-high-end equipment and, therefore, reduces dependence on the operator's skills/ equipment, all of which may promote the widespread use of CEUS. As stated earlier, Sonazoid CEUS provides very stable postvascular phase images for up to 60-120 min\cite{12}, which has resulted in the invention of the breakthrough method, defect reperfusion imaging that is an innovative technology that will greatly change the daily practices of HCC management. In our study, the diagnostic sensitivity of Sonazoid CEUS was 67.6% in all HCC, and 79.2% in moderately-differentiated HCC.

Kudo \textit{et al}\cite{11,12,13} have recently developed defect reperfusion imaging (using the properties of very stable Kupffer phase images and real-time fine blood flow images obtained with Sonazoid) for typical HCC, which is depicted by CT but not by B mode scanning. The method is a breakthrough for accurate localization and treatment guidance\cite{8}; dramatic resolution of many limitations in the diagnosis and treatment of HCC, such as detection of small HCC\cite{10}, evaluation of treatment response\cite{10}, and needle insertion guidance; additionally, detection is even more sensitive than with MDCT\cite{10}.

A newly introduced contrast agent, Gd-EOB-DTPA, approved in Japan in 2008, is a hepatocyte-specific MRI contrast medium with a different mechanism that utilizes neither dynamic nor Kupffer cell imaging. It is useful in cases which would be difficult to diagnose by techniques such as dynamic MRI or SPIO-MRI. Typical HCC shows high intensity with Gd-EOB-DTPA in the arterial-dominant phase and low intensity in the portal-dominant phase and thereafter. The imaging diagnosis of HCC can be made approximately 10-20 min after the injection of Gd-EOB-DTPA. In our study, the diagnostic sensitivity of Gd-EOB-DTPA MRI was 76.5% in all nodules and 75.0% in moderately-differentiated HCC.

Previously, we had concluded that CT arteriportal angiography was superior to CECT and Gadolinium-enhanced MRI for diagnosing HCC in nodules smaller than 2 cm\cite{11}. In this study, the diagnostic sensitivity of CT arteriportal angiography was 88.2% in all nodules and 95.8% in moderately-differentiated HCC. We observed a significant difference between CECT and CT arteriportal angiography ($P < 0.05$) in all nodules. However, there was no difference between Sonazoid CEUS, Gd-EOB-DTPA MRI, and CT arteriportal angiography. The combined sensitivity of Sonazoid CEUS and Gd-EOB-DTPA MRI in all nodules was 94.1%, due to improvement in the diagnostic capabilities of Sonazoid CEUS and Gd-EOB-DTPA MRI. This improvement in these two imaging modalities with the use of the newly introduced contrast agents provided higher sensitivity for the diagnosis of nodules smaller than 2 cm with Sonazoid CEUS and Gd-EOB-DTPA MRI than with Sonovue CEUS and CECT reported by Bolondi \textit{et al}\cite{10}, or with Sonovue CEUS and Gadolinium-enhanced MRI reported by Forner \textit{et al}\cite{10}.

These results, considered together with the invasiveness of CT arteriportal angiography, suggest that the principal diagnostic modality for HCC smaller than 2 cm

\begin{figure}[ht]
\centering
\includegraphics[width=\textwidth]{figure2.png}
\caption{Case No. 2: detection by gadolinium-ethoxybenzyl-diethylenetriamine pentaacetic acid magnetic resonance imaging. Imaging and histological findings of the nodule in segment six. A: Ultrasonography (US) reveals an 8 mm hyperechoic nodule (arrow); B: Gadolinium-ethoxybenzyl-diethylenetriamine pentaacetic acid magnetic resonance imaging reveals a defect (arrow) in the hepatobiliary phase; C: The nodule is diagnosed as well-differentiated hepatocellular carcinoma by US-guided biopsy, showing cellularity more than two-fold that of the non-tumorous area.}
\end{figure}
should be changed from CT arterioporal angiography to Sonazoid CEUS and Gd-EOB-DTPA MRI.

**REFERENCES**

1. Termination of nodular hepatocellular lesions. International Working Party. *Hepatology* 1995; 22: 983-993.
2. Theise ND, Schwartz M, Miller C, Thung SN. Macrogenetic nodules and hepatocellular carcinoma in forty-four sequential adult liver explants with cirrhosis. *Hepatology* 1992; 16: 949-955.
3. Mion F, Groezl Z, Boillot O, Panier P, Berger F. Adult cirrhotic liver explants: precancerosous lesions and undetected small hepatocellular carcinomas. *Gastroenterology* 1996; 111: 1387-1392.
4. Burrell M, Llovet JM, Ayuso C, Iglesias C, Sala M, Miguel R, Caralt M, Ayuso JR, Solé M, Sanchez M, Brú C, Bruix J. MRI angiography is superior to helical CT for detection of HCC prior to liver transplantation: an explant correlation. *Hepatology* 2003; 38: 1034-1042.
5. Hayashi M, Matsui O, Ueda K, Kawamori Y, Gabata T, Kadoya M. Progression to hypervascular hepatocellular carcinoma: correlation with intranodular blood supply evaluated with CT during intraarterial injection of contrast material. *Radiology* 2002; 225: 143-149.
6. Tajima T, Honda H, Taguchi K, Asayama Y, Kuroiwa T, Yoshimitsu K, Irie H, Aibe H, Shimada M, Masuda K. Sequential hemodynamic change in hepatocellular carcinoma and dysplastic nodules: CT angiography and pathologic correlation. *AJR Am J Roentgenol* 2002; 178: 885-897.
7. Kim SR, Ando K, Mita K, Fuki S, Ikawa H, Kanbara Y, Imoto S, Matsuoka T, Hayashi Y, Kudo M. Superiority of CT arterioporal angiography to contrast-enhanced CT and MRI in the diagnosis of hepatocellular carcinoma in nodules smaller than 2 cm. *Oncoology* 2007; 72 Suppl 1: 58-66.
8. Kudo M, Hatanaka K, Chung H, Minami Y, Maekawa K. A proposal of novel treatment-assist technique for hepatocellular carcinoma in the sonazoid-enhanced ultrasonography: value of defect re-perfusion imaging (in Japanese). *Kanzo* 2007; 48: 299-301.
9. Bruix J, Sherman M, Llovet JM, Beaugrand M, Lencioni R, Burroughs AK, Christensen E, Pagliaro L, Collombo M, Rodés J. Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver. *J Hepatol* 2001; 35: 421-430.
10. Bolondi L, Gaiani S, Celi N, Golferini R, Grigioni W, Leoni S, Venturi AM, Pas高铁a C. Characterization of small nodules in cirrhosis by assessment of vascularity: the problem of hypo-vascular hepatocellular carcinoma. *Hepatology* 2005; 42: 27-34.
11. Forner A, Vilanova R, Ayuso C, Bianchi L, Solé M, Ayuso JR, Boix L, Sala M, Varela M, Llovet JM, Brú C, Bruix J. Diagnosis of hepatic nodules 20 mm or smaller in cirrhosis: Prospective validation of the noninvasive diagnostic criteria for hepatocellular carcinoma. *Hepatology* 2008; 47: 99-104.
12. Inoue T, Kudo M, Hatanaka K, Takahashi S, Kitai S, Ueda T, Ishikawa E, Hagiwara S, Minami Y, Chung H, Ueshima K, Maekawa K. Imaging of hepatocellular carcinoma: qualitative and quantitative analysis of postvascular phase contrast-enhanced ultrasonography with sonazoid. Comparison with superparamagnetic iron oxide magnetic resonance images. *Oncology* 2008; 75 Suppl 1: 48-54.
13. Kudo M, Hatanaka K, Maekawa K. Defect reperfusion imaging, a newly developed novel technology using sonazoid in the treatment of hepatocellular carcinoma. *J Med Ultrasound* 2008; 16: 130-139.
14. Kudo M, Hatanaka K, Maekawa K. Sonazoid-enhanced ultrasonography in the diagnosis and treatment of hepatic tumors. *J Med Ultrasound* 2008; 16: 130-139.
15. Hatanaka K, Kudo M, Minami Y, Maekawa K. Sonazoid-enhanced ultrasonography for diagnosis of hepatic malignancies: comparison with contrast-enhanced CT. *Oncology* 2008; 75 Suppl 1: 42-47.
16. Xia Y, Kudo M, Minami Y, Hatanaka K, Ueshima K, Chung H, Hagiwara S, Inoue T, Ishikawa E, Kitai S, Takahashi S, Tatsumi C, Ueda T, Hayashi S, Maekawa K. Response evaluation of transcatheter arterial chemoembolization in hepatocellular carcinomas: the usefulness of sonazoid-enhanced harmonic sonography. *Oncology* 2008; 75 Suppl 1: 99-105.